Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 11;11(12):1894. doi: 10.3390/cells11121894

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Inhibition of MLKL does not affect cGAS–STING pathway in renal I/R injury. (A) Immunoblot and graph showing increases in the levels of cl-RIP1 and reductions in RIP1 levels after renal I/R injury compared to sham group. Values are expressed as means ± SEM; * p < 0.05 versus sham group (n = 3/group). (B) Immunoblot and graph showing dramatic increases in MLKL levels after renal I/R injury compared to sham group. Values are expressed as means ± SEM; * p < 0.05 versus sham group (n = 3/group). (C) Immunoblots showing no changes in cGAS, STING, and Mitofilin levels in kidneys treated with different doses (0, 2.5, 5, and 10 mg/kg) of MLKL inhibitor after renal I/R injury. Note that all doses of the MLKL inhibitor were able to significantly reduce the MLKL phosphorylation; * p < 0.05 versus sham group; ^# p < 0.05 versus I/R+0mg/kg group (n = 3/group).